JP6779873B2 - 抗コンドロイチン硫酸プロテオグリカン４抗体およびその使用 - Google Patents

抗コンドロイチン硫酸プロテオグリカン４抗体およびその使用 Download PDF

Info

Publication number
JP6779873B2
JP6779873B2 JP2017525343A JP2017525343A JP6779873B2 JP 6779873 B2 JP6779873 B2 JP 6779873B2 JP 2017525343 A JP2017525343 A JP 2017525343A JP 2017525343 A JP2017525343 A JP 2017525343A JP 6779873 B2 JP6779873 B2 JP 6779873B2
Authority
JP
Japan
Prior art keywords
antibody
cells
humanized
bispecific
bispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017525343A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537082A5 (enExample
JP2017537082A (ja
Inventor
ソルダーノ フェローン，
ソルダーノ フェローン，
ナイ−コン ブイ． チュン，
ナイ−コン ブイ． チュン，
ミン チェン，
ミン チェン，
Original Assignee
メモリアル スローン ケタリング キャンサー センター
メモリアル スローン ケタリング キャンサー センター
ザ ジェネラル ホスピタル コーポレイション
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, メモリアル スローン ケタリング キャンサー センター, ザ ジェネラル ホスピタル コーポレイション, ザ ジェネラル ホスピタル コーポレイション filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2017537082A publication Critical patent/JP2017537082A/ja
Publication of JP2017537082A5 publication Critical patent/JP2017537082A5/ja
Application granted granted Critical
Publication of JP6779873B2 publication Critical patent/JP6779873B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017525343A 2014-11-12 2015-11-12 抗コンドロイチン硫酸プロテオグリカン４抗体およびその使用 Expired - Fee Related JP6779873B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462078849P 2014-11-12 2014-11-12
US62/078,849 2014-11-12
PCT/US2015/060465 WO2016077638A1 (en) 2014-11-12 2015-11-12 Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2017537082A JP2017537082A (ja) 2017-12-14
JP2017537082A5 JP2017537082A5 (enExample) 2018-12-20
JP6779873B2 true JP6779873B2 (ja) 2020-11-04

Family

ID=55955081

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017525343A Expired - Fee Related JP6779873B2 (ja) 2014-11-12 2015-11-12 抗コンドロイチン硫酸プロテオグリカン４抗体およびその使用

Country Status (6)

Country Link
US (1) US11091547B2 (enExample)
EP (1) EP3218413A4 (enExample)
JP (1) JP6779873B2 (enExample)
AU (1) AU2015346205B2 (enExample)
CA (1) CA2967350C (enExample)
WO (1) WO2016077638A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3074025A1 (en) 2013-11-27 2016-10-05 Baylor College Of Medicine Csgp4-specific chimeric antigen receptor for cancer
US12428490B2 (en) 2018-06-13 2025-09-30 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells
CA3117212A1 (en) 2018-10-23 2020-04-30 Dragonfly Therapeutics, Inc. Heterodimeric fc-fused proteins
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
EP4138778A1 (en) 2020-04-22 2023-03-01 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric fc-fused proteins
CN111575241B (zh) * 2020-05-29 2022-09-13 复旦大学附属眼耳鼻喉科医院 一种嵌合硫酸软骨素蛋白多糖4受体的t淋巴细胞及其制备方法和用途
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2022006147A1 (en) * 2020-06-29 2022-01-06 Cell Medica Inc. Methods and compositions for the reduction of chimeric antigen receptor tonic signaling
CN114249832B (zh) * 2020-09-24 2023-11-10 博源润生医药（杭州）有限公司 一种靶向cpsg4的人源化嵌合抗原受体及表达该嵌合抗原受体的免疫效应细胞及其应用
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
AU2022262350B2 (en) 2021-04-20 2026-05-07 Terrapower Isotopes, Llc Titania based generators for ac-225 generation
WO2022251253A1 (en) 2021-05-24 2022-12-01 Provention Bio, Inc. Methods for treating type 1 diabetes
AU2022287014A1 (en) * 2021-06-04 2023-12-07 Amgen Inc. T cell engager molecules and uses thereof
WO2023107538A2 (en) * 2021-12-07 2023-06-15 Regents Of The University Of Minnesota Binders of chondroitin sulfate proteoglycan (cspg4) polypeptides

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US20130183288A1 (en) * 2007-03-28 2013-07-18 Biogen Idec Inc. Non-fucosylated antibodies
WO2010033866A2 (en) 2008-09-19 2010-03-25 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma
WO2010045495A2 (en) * 2008-10-16 2010-04-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
US8318162B2 (en) * 2009-07-16 2012-11-27 Xoma Technology Ltd. Antibodies to high molecular weight melanoma associated antigen
KR101508043B1 (ko) 2009-09-29 2015-04-06 로슈 글리카트 아게 이중특이적 사멸 수용체 아고니스트성 항체
ES2961381T3 (es) * 2010-06-19 2024-03-11 Memorial Sloan Kettering Cancer Center Anticuerpos anti-GD2
WO2012075324A1 (en) * 2010-12-02 2012-06-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating a tumor using an antibody that specifically binds hmw-maa
JP6441079B2 (ja) * 2011-12-19 2018-12-19 シンイミューン ゲーエムベーハー 二重特異性抗体分子
CN104114187A (zh) * 2011-12-28 2014-10-22 诺沃姆德治疗公司 去糖基化的人类抗体、其融合蛋白质及用途
ES2924722T3 (es) 2012-05-18 2022-10-10 Aptevo Res & Development Llc Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3
WO2014131712A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
JP6420776B2 (ja) * 2013-03-05 2018-11-07 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 免疫療法のためのエンゲージャー細胞
US10220091B2 (en) * 2013-04-04 2019-03-05 The General Hospital Corporation Combination treatments with sonic hedgehog inhibitors

Also Published As

Publication number Publication date
CA2967350A1 (en) 2016-05-19
WO2016077638A1 (en) 2016-05-19
US11091547B2 (en) 2021-08-17
EP3218413A1 (en) 2017-09-20
US20170342151A1 (en) 2017-11-30
AU2015346205B2 (en) 2021-07-29
AU2015346205A1 (en) 2017-06-01
JP2017537082A (ja) 2017-12-14
CA2967350C (en) 2021-11-23
EP3218413A4 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
US11091547B2 (en) Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof
US11981742B2 (en) Antibody agents specific for human CD19 and uses thereof
CN109715667B (zh) 抗-gprc5d抗体、结合gprc5d和cd3的双特异性抗原结合分子及其用途
US10844122B2 (en) Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
US9884921B2 (en) Bispecific heterodimeric diabodies and uses thereof
US20240150464A1 (en) Materials and methods for modulating t cell mediated immunity
CN108495864A (zh) 抗ror1抗体、ror1×cd3双特异性抗体及其使用方法
KR20220035367A (ko) 항-dll3 키메라 항원 수용체 및 이의 용도
TWI910464B (zh) 新型抗cd19抗體
KR20220114559A (ko) Cd38에 결합하는 중쇄 항체
KR20210086651A (ko) Cd38에 결합하는 중쇄 항체
CA3189473A1 (en) Novel human antibodies binding to human cd3 epsilon
US20240327509A1 (en) Human cxcli6 antibodies and the use thereof
JP2026503077A (ja) 抗ｔｎｆｒ２抗原結合タンパク質及びその使用
HK40110049A (zh) 对人和食蟹猴蛋白具有交叉反应性的抗cd3抗体
CN120958019A (zh) 针对人分化簇3蛋白的抗体及其变体
HK40108102A (zh) 具有改善的治疗指数的靶向cd3的t细胞衔接器
HK1241907B (zh) 对人类cd19具有专一性的抗体药剂和其用途
HK1241907A1 (en) Antibody agents specific for human cd19 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190827

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200515

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200925

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201014

R150 Certificate of patent or registration of utility model

Ref document number: 6779873

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees